News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QT 5, Inc. Expands NICOWater(TM) Distribution Network



10/19/2005 5:10:45 PM

WESTLAKE VILLAGE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- QT 5, Inc. (BULLETIN BOARD: QTFV) , manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings, today announced the addition of four new distribution partners in the Northeastern U.S. The group includes; Bull Dog Beverage serving Northern New Jersey and all five boroughs of New York City, Native Wholesale Company serving Central New York, Northern Pennsylvania and all of West Virginia, Amoskeag Beverages, Inc. serving all of New Hampshire, and Bev Net who will be taking over the Connecticut markets.

"We continue to recruit and secure new distributors at an aggressive pace," said Steven H. Reder, QT 5, Inc. President. "Since we first announced the availability of NICOWater(TM), we have been flooded with interest from distributors, dealers and consumers. In strict adherence to our rollout strategies, we have been very careful to assure the capability, credibility and potential of each new partner. I am proud to say that each of these new NICOWater(TM) distributors are recognized leaders in their channels."

About QT 5, Inc.

QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of Bio-Med testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5 continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: http://www.qt5inc.com/. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause the results of QT 5, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes no obligation and does not intend to update these forward-looking statements.

QT 5, Inc.

CONTACT: Steve Reder, President of QT 5, Inc., +1-818-338-1510,sreder@qt5inc.com; or Peter Berk, +1-310-274-1072, ext. 205,peter@crierpr.com, or J.P. Lincoln, +1-310-274-1072, ext. 201, jp@crierpr.comboth of Crier Communications for QT 5, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES